Every Form 4 that Firefly Neuroscience, Inc. (AIFF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIFF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIFF filings page.
FIREFLY NEUROSCIENCE, INC. director and President & COO David DeCaprio reported acquiring 44,872 shares of Common Stock, received as a grant or award at a price of $0.00 per share. After this vesting event, he directly owns 77,866 Common Stock shares.
The shares relate to restricted stock units originally granted on April 18, 2025 for 263,952 shares under the 2024 Long-Term Incentive Plan. On March 10, 2026, the Compensation Committee determined the performance conditions were met, triggering vesting of these 44,872 shares as part of that larger award.
FIREFLY NEUROSCIENCE, INC. Chief Executive Officer Gregory Lipschitz reported an equity compensation vesting rather than a market trade. On March 10, 2026, he acquired 65,988 shares of Common Stock at a price of $0.0000 per share through a grant/award.
These shares relate to restricted stock units granted on April 18, 2025 for 395,927 shares under the 2024 Long-Term Incentive Plan, after the compensation committee determined performance conditions had been met for 65,988 shares. Following this vesting, he holds 530,184 shares, including 464,196 held by Bower Four Capital Corporation and 65,988 shares held directly.
Firefly Neuroscience (AIFF) reported an insider equity grant. A company director received 73,892 deferred stock units (DSUs) on October 28, 2025 under the 2024 Long‑Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock. Following this transaction, the reporting person held 90,559 derivative securities on a direct ownership basis. The DSUs were reported at a $0.00 price.
Firefly Neuroscience (AIFF) reported a director equity award. On October 28, 2025, the reporting person received 49,262 deferred stock units (DSUs) under the 2024 Long‑Term Incentive Plan. These DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the award, the filing lists 65,929 derivative securities beneficially owned, held directly. The transaction was coded as an acquisition at a stated price of $0.00, consistent with a standard equity grant for board service.
Firefly Neuroscience, Inc. (AIFF) disclosed a Form 4 showing a director received 49,262 deferred stock units (DSUs) on October 28, 2025 under the Issuer's 2024 Long-Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the grant, 65,929 derivative securities were beneficially owned, held directly. The transaction price for the DSUs was $0.00.
Firefly Neuroscience (AIFF): A reporting group led by Windsor Private Capital disclosed open‑market sales of common stock under Rule 144. On 10/20/2025 they sold 33,500 shares at $2.457; on 10/21/2025 they sold 19,222 shares at $2.4004; and on 10/22/2025 they sold 78,031 shares at $2.0727.
Following these transactions, the group states it is no longer a beneficial owner of more than 10% of the company’s securities. After the final sale, 1,236,773 shares were beneficially owned indirectly, held through Windsor, per the filing footnotes.
Firefly Neuroscience (AIFF) insiders reported open‑market sales by a group affiliated with Windsor Private Capital. On 10/15/2025, 17,500 shares were sold at an average price of $2.7444; on 10/16/2025, 40,139 shares at $2.6522; and on 10/17/2025, 45,036 shares at $2.5462. Following these transactions, the group reported 1,452,701, then 1,412,562, and finally 1,367,526 shares beneficially owned. The filing notes these sales were conducted under Rule 144 and that the holdings are reported as indirectly owned through Windsor, with the reporting persons identified as members of a group that beneficially owns more than 10%.
Firefly Neuroscience (AIFF): insider group reports open-market sales
A group of reporting persons led by Windsor Private Capital LP, identified as more than 10% beneficial owners, disclosed multiple sales of Firefly Neuroscience common stock under Rule 144. Reported transactions include sales on 10/09/2025 (30,126 shares at $2.9441), 10/10/2025 (74,810 shares at $2.6994), 10/13/2025 (32,136 shares at $2.6525), and 10/14/2025 (29,500 shares at $2.739). Following these trades, the group reports 1,470,201 shares beneficially owned indirectly.
The securities are held by Windsor; related entities and individuals (including WPC entities and certain officers) may be deemed beneficial owners, with stated disclaimers of beneficial ownership except to the extent of pecuniary interest.